|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2009
|
|
gptkbp:associatedWith
|
gptkb:sirolimus
gptkb:temsirolimus
|
|
gptkbp:ATCCode
|
L01EG02
|
|
gptkbp:brand
|
gptkb:everolimus
|
|
gptkbp:CASNumber
|
gptkb:159351-69-6
|
|
gptkbp:chemicalFormula
|
C53H83NO14
|
|
gptkbp:contraindication
|
hypersensitivity to everolimus
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Afinitor
|
|
gptkbp:indication
|
gptkb:advanced_hormone_receptor-positive,_HER2-negative_breast_cancer
gptkb:advanced_renal_cell_carcinoma
tuberous sclerosis complex-associated renal angiomyolipoma
progressive neuroendocrine tumors of pancreatic origin
tuberous sclerosis complex-associated subependymal giant cell astrocytoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:mechanismOfAction
|
mTOR inhibitor
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
infections
rash
stomatitis
|
|
gptkbp:usedFor
|
gptkb:tuberous_sclerosis_complex
gptkb:cancer
gptkb:pancreatic_neuroendocrine_tumors
gptkb:subependymal_giant_cell_astrocytoma
renal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
4
|